Mark Stejbach Biography and Net Worth

Director of Indivior

Mark Stejbach joined our Board in March 2021. With more than 30 years in biotech and pharmaceuticals, he has held senior commercial roles at Alkermes, Tengion, Merck, and Biogen, including leading the commercialization of addiction and schizophrenia treatments. Mark also served as a director at Flexion Therapeutics and as Senior Commercial Advisor to EIP Pharma.

Mark earned his MBA from the Wharton School of the University of Pennsylvania and a BS in Mathematics from Virginia Tech. His expertise lies in building sustainable commercial strategies that put individuals at the center.

What is Mark Stejbach's net worth?: The estimated net worth of Mark Stejbach is at least $548.08 thousand as of January 5th, 2026. Stejbach owns 16,847 shares of Indivior stock worth more than $548,083 as of January 16th. This net worth approximation does not reflect any other investments that Stejbach may own. Learn More about Mark Stejbach's net worth.
How do I contact Mark Stejbach?: The corporate mailing address for Stejbach and other Indivior executives is 10710 Midlothian Turnpike, North Chesterfield, VA 23235, United States. Indivior can also be reached via phone at 804-379-1090 and via email at [email protected]. Learn More on Mark Stejbach's contact information.
Has Mark Stejbach been buying or selling shares of Indivior?: Within the last three months, Mark Stejbach has bought $27,427.25 in shares of Indivior stock. Most recently, on Monday, January 5th, Mark Stejbach bought 775 shares of Indivior stock. The stock was acquired at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the transaction, the director now directly owns 16,847 shares of the company's stock, valued at $596,215.33. Learn More on Mark Stejbach's trading history.
Who are Indivior's active insiders?: Indivior's insider roster includes Keith Humphreys (Director), Daniel Ninivaggi (Director), Barbara Ryan (Director), Mark Stejbach (Director), and David Wheadon (Director). Learn More on Indivior's active insiders.
Are insiders buying or selling shares of Indivior?: In the last twelve months, Indivior insiders bought shares 5 times. They purchased a total of 4,871 shares worth more than $172,384.69. The most recent insider tranaction occured on January, 5th when Director Barbara Ryan bought 775 shares worth more than $27,427.25. Learn More about insider trades at Indivior.
Information on this page was last updated on 1/5/2026.

Mark Stejbach Insider Trading History at Indivior

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/5/2026	Buy	775	$35.39	$27,427.25	16,847

Mark Stejbach Buying and Selling Activity at Indivior

Indivior Company Overview

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Today's Range

Now: $32.54

$32.16

$33.10

50 Day Range

MA: $34.34

$29.83

$36.60

2 Week Range

Now: $32.54

$7.62

$38.00

Volume

2,317,098 shs

Average Volume

2,192,063 shs

Market Capitalization

$4.07 billion

P/E Ratio

35.37

Dividend Yield

N/A

Beta

0.75